News

Safety Shot Appoints New CFO Danielle De Rosa

Moving headquarters to Scottsdale, Arizona closer to production, distribution, and major markets JUPITER, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) --…

2 years ago

Ibogaine by David Dardashti Optimizes Algorithm for Fentanyl Treatment

Innovative Treatment Protocol Aims to Revolutionize Fentanyl TreatmentMIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- For those struggling with fentanyl addiction,…

2 years ago

G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today…

2 years ago

Cerevance Announces Presentation at AD/PD™ 2024 International Conference

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system…

2 years ago

Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024

CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine…

2 years ago

Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy

SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- – Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and…

2 years ago

GLUCOTRACK SELECTS CIRTEC MEDICAL AS MANUFACTURER FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

Rutherford, NJ & Brooklyn Park, MN, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company…

2 years ago

Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy

Presentations include data for WVE-N531 that provide first clinical evidence of a potential therapeutic for DMD accessing satellite cells, which…

2 years ago

Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE)…

2 years ago